Fidelio Capital acquires Premune’s shares in Nextmune

December 15, 2020

We are pleased to announce that, effective 24 November 2020, Fidelio Capital AB (“Fidelio”) has completed the acquisition of Premune AB’s (“Premune”) shares in Nextmune. Through the transaction, Fidelio will increase its ownership in Nextmune and become the majority owner. Nextmune is a leading company within specialty pharmaceuticals for companion animals with sales in over 75 markets worldwide.

With Fidelio as the majority owner, Nextmune will have the support and resources to continue to invest in innovation and R&D and to broaden its product portfolio. The transaction will not lead to any operational changes in the company, which will continue to run in the same way as today.

Fidelio looks forward to continuing to support Nextmune on its journey to improve the quality of life for companion animals around the world.

Recent news

First day of trading in Vimian’s shares on …

Vimian Group AB (publ) (“Vimian”, the “Group” or the “Company”), a global, fast-growing and innovation-driven animal health business, offering products, services and solutions to veterinary professionals, labs and pet parents around the world, today announces the listing of and commencement

Read more

Vimian announces intention to list on Nasdaq Firs…

Vimian Group AB (publ), a global, fast-growing and innovation-driven animal health business, offering products, services and solutions to veterinary professionals, labs and pet parents around the world, announces its intention to carry out a private placement of shares in the

Read more

Fidelio forms Vimian – a global powerhouse …

Following a decade of successfully shaping market leaders across the rapidly evolving animal health market, Fidelio Capital AB (Fidelio) today announced the formation of Vimian – a global and diversified group of innovation-driven companies operating in four fast-growing animal health

Read more